The immunoenhancing effects of sorafenib was later observed in different studies where reduced abundance of immunosuppressive Treg cells and MDSCs, and augmented function and migration of CD8+ T cells supported an immune-permissive tumor microenvironment which might potentiate adoptive T-cell therapy [43, 44]. The gene discussed is CD8A; the disease is neoplasm.